The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement ...

The stock's fall snapped a three-day winning streak.

This was the stock's second consecutive day of gains.

In a report released today, Jessica Fye from J.P. Morgan maintained a Hold rating on Incyte (INCY – Research Report). The company’s shares ...

The authors explore the shifting and opaque landscape facing companies that are required to maintain policies addressing the ...

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 15.2% in the pre-market session after the company released phase three trial data for a skin condition treatment ...

Shares of Incyte Co. (NASDAQ:INCY – Get Free Report) have been given a consensus recommendation of “Hold” by the nineteen ...

Piotr Swat / SOPA Images / LightRocket / Getty Images Incyte shares sank Monday after the drugmaker released the latest data from a clinical trial. The drug, povorcitinib, accomplished its goal of ...

Syndax has a strong cash position and a significant market opportunity with Revuforj and Niktimvo. Check out my ...

Incyte Corporation (NASDAQ:INCY), a biopharmaceutical company specializing in oncology and dermatology, finds itself at a critical juncture as it navigates the impending loss of patent protection ...